ARTICLES
211 Infant Peanut Introduction Simplified
Wade T.A. Watson, Edmond S. Chan
219 Allergy Testing and Immunotherapy
Alanna G. Wong, Jeanne M. Lomas
229 Immunodeficiency Disorders
Ivan K. Chinn, Jordan S. Orange

INDEX OF SUSPICION
243 Case 1: Cardiac Arrest in a 2-month-old Boy with a Prenatal Course Complicated by Alloimmunization
247 Case 2: Acute Onset and Worsening of Anemia in a 3-year-old Boy
Sofia Khera, Zoabe Hafeez, Amanda Padilla
251 Case 3: Pain and Weakness in a 12-year-old Boy
Hillary Seidenberg, Deepa Kulkarni
254 Case 4: Thrombocytopenia and Hematochezia in an Infant
Alexandra Schaller, Angela Myers, Shakila Khan, Avni Joshi, Vilmarie Rodriguez, George Maher

IN BRIEFS
256 Enthesitis-Related Juvenile Idiopathic Arthritis
Ayelet Rosenthal, Ginger Janow
259 Pediatric Osteoporosis
Coral L. Steffey
261 Correction

ONLINE
e18 Visual Diagnosis: Melena in a 13-month-old Girl
Malinda Wu, Meghan Kessler, Brett W. Engbrecht, Mark Tulchinsky, Michael M. Moore, Chandran P. Alexander
The journal extends special thanks to the following question writers and ancillary reviewers who contributed to this issue:

- E. Steve Roach, MD, disclosed he receives an honorarium from Elsevier for serving as editor of Pediatrics in Review.

- Miriam Weinstein, MD, disclosed the following paid consultant relationships: Paladin Labs, for participating in a product review; RX Briefcase, for consulting on a pharmacist training program on managing eczema; Johnson and Johnson, for participating in the advisory board; and Pfizer, Inc. for participating in the advisory board for an eczema product.

- Mark F. Weems, MD disclosed that he has a paid consultant relationship with Abbott Structural Heart as a member of the medical advisory board for the Amplatzer Piccolo PDA Occluder.

Each of the editorial board members, reviewers, question writers, PREP Coordinating Committee members and staff has disclosed, if applicable, that the CME content he/she edits writes reviews may include discussion reference to generic pharmaceuticals, off-label pharmaceutical use, investigational therapies, brand names, and manufacturer's of those in a position to influence and control the content of AAP CME activities. All individuals in a position to influence and control the content of AAP CME activities are required to disclose any potential conflicts of interest.

Each of the editorial board members, reviewers, question writers, PREP Coordinating Committee members and staff has disclosed, if applicable, that the CME content he/she edits writes reviews may include discussion reference to generic pharmaceuticals, off-label pharmaceutical use, investigational therapies, brand names, and manufacturers. None of the editors, board members, reviewers, question writers, PREP Coordinating Committee members, or staff has any relevant financial relationships to disclose, unless noted below. The AAP has taken steps to resolve any potential conflicts of interest.

Disclosures

- Nupur Gupta, MD, disclosed that she receives royalties from Springer as the co-editor of the MassGeneral Hospital for Children Handbook of Pediatric Global Health and that her spouse has a stock/bond relationship with Amarin.
- Neal LeLeiko, MD, PhD, disclosed he owns stocks/bonds in Celgene Corp. and serves as a paid consultant to AbbVie Inc. as a member of the data monitoring board of an investigational drug potentially of use in inflammatory bowel disease.
- Mobeen Rathore, MD, CPE, disclosed that he is a member of the advisory boards for Squire and GSK and is a consultant for Viv Healthcare.
- E. Steve Roach, MD, disclosed he receives an honorarium from Elsevier for serving as editor of Pediatric Neurology.
- Mark F. Weems, MD, disclosed that he has a paid consultant relationship with Abbott Structural Heart as a member of the medical advisory board for the Amplatzer Piccolo PDA Occluder.
- Miriam Weinstein, MD, disclosed the following paid consultant relationships: Paladin Labs, for participating in a product review; RX Briefcase, for consulting on a pharmacist training program on managing eczema; Johnson and Johnson, for participating in the advisory board; and Pfizer, Inc. for participating in the advisory board for an eczema product.

The journal extends special thanks to the following question writers and ancillary reviewers who contributed to this issue:

- Neal S. LeLeiko, Providence, RI
- Michael Macknin, Cleveland, OH
- Susan Massengill, Charlotte, NC
- Elaine M. Pereira, New York, NY
- Peter Pizzutillo, Philadelphia, PA
- Mobeen Rathore, Jacksonville, FL
- Jennifer S. Read, Rockville, MD
- E. Steve Roach, Austin, TX
- Sarah E. Shea, Halifax, Nova Scotia
- Andrew Sirotnak, Denver, CO
- Miriam Weinstein, Toronto, ON
- Shabana Yusuf, Houston, TX

The American Academy of Pediatrics (AAP) Policy on Disclosure of Financial Relationships and Resolution of Conflicts of Interest for AAP CME Activities is designed to ensure quality, objective, balanced, and scientifically rigorous AAP CME activities by identifying and resolving all potential conflicts of interest before the confirmation of service of those in a position to influence and control CME content. All individuals in a position to influence and control the content of AAP CME activities are required to disclose any potential conflicts of interest. The American Academy of Pediatrics (AAP) designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pediatricians in Review offers 36 CME articles per year. A maximum of one AMA PRA Category 1 Credit™ is earned after achieving a 60% on each designated quiz. 2019 Pediatrics in Review is approved for a total of 30 Maintenance of Certification (MOC) Part 2 credits by the American Board of Pediatrics through the AAP MOC Portfolio Program.

CME STATEMENTS:
The American Academy of Pediatrics (AAP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AAP designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity is acceptable for a maximum of 1.00 AAP credit. These credits can be applied toward the AAP CME/CPP® Award available to Fellows and Candidate Members of the AAP. The American Academy of Physician Assistants accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. PhysicAssistants may receive a maximum of 1.00 hour of Category 1 credit for completing this program.

This program is accredited for 1.00 NAPNAP CPD contact hours; pharmacology (Rx) and psychopharmacology contact hours to be determined per the National Association of Pediatric Nurse Practitioners (NAPNAP) Continuing Education Guidelines. It has been established that each CME activity will take the learner approximately 1 hour to complete. *Continuing Professional Development

How to complete this activity:
Pediatrics in Review can be accessed and reviewed in print or online at http://pedsinreview.aappublications.org. Learners can claim credit monthly online upon completion of each CME article. The deadline for completing this activity is December 31, 2021. Credit will be recorded in the year in which it is submitted. It is estimated that it will take approximately 1 hour to complete each CME article. This activity is not considered to have been completed until the learner documents participation in that activity to the provider via online submission of answers. Course evaluations are online.

MOC STATEMENT:
This activity is approved for 30.00 points of MOC Part 2 credit by the American Board of Pediatrics. All approved activities must be completed by the MOC Credit Approval End Date. All deadlines and MOC point values should be confirmed by checking the ABP Activity Catalog within each physician’s ABP Portfolio. Learners must complete a minimum of 30 quizzes from the 2019 Pediatrics in Review, with a minimum passing score of 60% on each, to earn 30 MOC Part 2 points.

End Date. All deadlines and MOC point values should be confirmed by checking the ABP Activity Catalog within each physician’s ABP Portfolio. Learners must complete a minimum of 30 quizzes from the 2019 Pediatrics in Review, with a minimum passing score of 60% on each, to earn 30 MOC Part 2 points.
Updated Information & Services
including high resolution figures, can be found at:
http://pedsinreview.aappublications.org/content/40/5

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
https://shop.aap.org/licensing-permissions/

Reprints
Information about ordering reprints can be found online:
http://classic.pedsinreview.aappublications.org/content/reprints